Pfizer (PFE) Debt to Equity (2009 - 2026)

Pfizer (PFE) has 18 years of Debt to Equity data on file, last reported at $0.72 in Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.72, up 4.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.72 (up 4.39% YoY), and the FY2025 annual result was $0.75, up 3.7% from the prior year.
• Debt to Equity retreated to $0.72 in Q1 2026 per PFE's latest filing, from $0.75 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.81 in Q4 2023 and troughed at $0.35 in Q2 2023.
• A 5-year average of $0.63 and a median of $0.69 in 2025 frame the typical range for Debt to Equity.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity plunged 64.38% in 2022, then soared 115.54% in 2023.
• A 5-year view of Debt to Equity shows it stood at $0.37 in 2022, then soared by 115.54% to $0.81 in 2023, then dropped by 10.25% to $0.72 in 2024, then advanced by 3.7% to $0.75 in 2025, then fell by 4.53% to $0.72 in 2026.
• Business Quant data shows PFE's Debt to Equity at $0.72 in Q1 2026, $0.75 in Q4 2025, and $0.66 in Q3 2025.